Antithrombin-III without concomitant heparin improves endotoxin-induced acute lung injury rats by inhibiting the activation of mitogen-activated protein kinase.

Hui-ming Sun,Ling-zhi Hong,Xiao-kun Shen,Xin-qing Lin,Yong Song,Yi Shi
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.2009.20.013
IF: 6.133
2009-01-01
Chinese Medical Journal
Abstract:Background Antithrombin-III (AT-III), the major inhibitor of thrombin in plasma, also has anti-inflammation property and might have positive effect on sepsis. The present study aimed to investigate the effects of AT-III on inflammatory reaction and pulmonary protection in endotoxin-induced acute lung injury (ALI) rat. Methods Sixty male Sprague-Dawley rats were randomly assigned equally to normal control group, ALI group, AT-III treatment group, AT-III+heparin treatment group, and heparin treatment group. The pulmonary vascular permeability index (PVPI) was measured by single nuclide tracer technique. The activity of AT-III in plasma was determined by the method of synthetic chromogenic substrata. Tumor necrosis factor-a (TNF-alpha) and interleukin-6 (IL-6) levels in serum were determined by enzyme-linked immunosorbent assay. The expressions of lung tissue mitogen-activated protein kinases (ERK1/2, P38 and JNK MAPK) were determined by Western blotting. Results Rats had significantly improved lung histopathology in the AT-III treatment group and heparin treatment group compared with the ALI group. The PVPI of the ALI group was 0.38+/-0.04, significantly higher than that of the normal control group (0.20+/-0.02, P <0.01), AT-III treatment group (0.30+/-0.04, P <0.01) and heparin treatment group (0.28+/-0.04, P <0.01) respectively. There were no significant differences of PVPI in the ALI group and AT-III+heparin treatment group. The activity of AT-III in plasma in the ALI group was (76+/-8)%, significantly lower than that of the normal control group ((96+/-11)%, P <0.05) and AT-III treatment group ((105+/-17)%, P <0.05) respectively. The serum levels of TNF-alpha and IL-6 of the ALI group were (2.770+/-0.373) mu g/L and (1.615+/-0.128) ng/ml respectively, significantly higher than those of the normal control group ((0.506+/-0.093) mu g/L and (0.233+/-0.047) ng/ml respectively, all P <0.01), AT-III treatment group ((1.774+/-0.218) mu g/L and (1.140+/-0145) ng/ml respectively, all P <0.01) and heparin treatment group ((1.924+/-0.349) mu g/L and (1.223+/-0.127) ng/ml respectively, all P <0.01). The lung tissue levels of phospho-ERK1/2 and phospho-P38 MAPK expressions were markedly higher in the ALI group than in the normal control group, AT-III treatment group and heparin treatment group respectively. Conclusions AT-III without concomitant heparin inhibited the activation of ERK1/2 and P38 MAPK, down-regulated the levels of downstream cytokines TNF-alpha and IL-6, relieved enclothelial permeability, and improved the ALI in enclotoxin-induced rats. It might be helpful to administrate AT-III alone, not with concomitant heparin, to those patients with ALI and sepsis. Chin Med J 2009;122(20):2466-2471
What problem does this paper attempt to address?